Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02237209 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

NIH

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSV LID ΔM2-2 Vaccine
BIOLOGICAL: Placebo Vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)